Alkermes PLC (ALKS) Q3 2026 Earnings Call Highlights: Proprietary Sales Surge 31% as Orexin ...
Alkermes PLC (ALKS) posted $480.1 million in total revenue and $417.3 million in proprietary product net sales, while outlining six orexin study readouts expected over the next year. Related Stocks: ALKS ,